Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 15;6(7):102184.
doi: 10.1016/j.xcrm.2025.102184.

Moving cellular therapies to the front line for Ph+ B cell acute lymphoblastic leukemia

Yanzhi Feng  1 , Etienne Leveille  1 , Jae H Park  2 , Markus Müschen  3
Affiliations

Moving cellular therapies to the front line for Ph+ B cell acute lymphoblastic leukemia

Yanzhi Feng et al. Cell Rep Med. .

Abstract

Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph+ B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability.1.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.H.P. received consulting fees from Adaptive Biotechnologies, Affyimmune Therapeutics, Allogene Therapeutics, Amgen, Artiva Biotherapeutics, Ascentage, Autolus, Beigene, Bright Pharmaceutical Services Inc., Caribou Bioscience, Curocell, Kite, Galapagos, Iovance, Jazz Pharmaceuticals, Medpace, Pfizer, Servier, Sobi, Synthekine, and Takeda. M.M. is a scientific advisory board member of Liangzhu Laboratory and the Versiti Blood Research Institute.

Figures

Figure 1
Figure 1
Study design, treatment strategy, and outcomes
See this image and copyright information in PMC

References

    1. Zhang M., Fu S., Feng J., Hong R., Wei G., Zhao H., Zhao M., Xu H., Cui J., Huang S., et al. Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 https://jamanetwork.com/journals/jamaoncology/fullarticle/2832720 Published online April 17, 2025. - PMC - PubMed
    1. Foà R., Bassan R., Vitale A., Elia L., Piciocchi A., Puzzolo M.C., Canichella M., Viero P., Ferrara F., Lunghi M., et al. Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N. Engl. J. Med. 2020;383:1613–1623. - PubMed
    1. Advani A.S., Moseley A., O’Dwyer K.M., Wood B.L., Park J., Wieduwilt M., Jeyakumar D., Yaghmour G., Atallah E.L., Gerds A.T., et al. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7:1279–1285. - PMC - PubMed
    1. Jabbour E., Short N.J., Jain N., Huang X., Montalban-Bravo G., Banerjee P., Rezvani K., Jiang X., Kim K.H., Kanagal-Shamanna R., et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet. Haematol. 2023;10:e24–e34. - PubMed
    1. Foà R., Bassan R., Elia L., Piciocchi A., Soddu S., Messina M., Ferrara F., Lunghi M., Mulè A., Bonifacio M., et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:881–885. - PMC - PubMed

MeSH terms

LinkOut - more resources